Back to mobile site

BMO Capital Reiterates Outperform Rating on Novartis (NVS)

November 25, 2024 8:27 AM EST Send to a Friend
BMO Capital analyst Etzer Darout reiterated an Outperform rating and $156.00 price target on Novartis (NYSE: NVS).The analyst commented, "Positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login